A Clinical Study for Inactivated Vaccine Against EV71

NCT02200237 Phase 2 COMPLETED

This study aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine in health children and infants aged from 2 months to \<12yrs.

Details

Lead sponsor	Medigen Vaccine Biologics Corp.
Phase	Phase 2
Status	COMPLETED
Enrolment	366
Start date	2014-09
Completion	2017-08

Conditions

• Enterovirus 71 Human

Interventions

• EV71 with adjuvant aluminium phosphate
• Placebo

Primary outcomes

• To evaluate overall safety of EV71 vaccine in children, throughout the study period — 2 years after study initiation
  Occurrence of overall adverse events and serious adverse events during the entire period of study.

Countries

Taiwan